The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial.
Sonja Baltic, David Nedeljkovic, Nikola Todorovic, Marijana Ranisavljev, Darinka Korovljev, Jelena Cvejic, Jelena Ostojic, Tyler W LeBaron, Judi Timmcke, Valdemar Stajer, Sergej M Ostojic · The journal of nutrition, health & aging · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease.
What the Findings Mean
Dihydrogen-PQQ resulted in a significant elevation in serum BDNF levels at the six-week follow-up (P = 0.01); conversely, no changes in BDNF levels were observed in the placebo group throughout the study duration (P = 0.27).
What the Researchers Studied
The study used a human clinical study. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
2.3 The experimental group was administered a daily dosage of dihydrogen-PQQ mixture, containing PQQ (20 mg) and dihydrogen-producing elemental magnesium (80 mg). The control group (placebo) received an equivalent amount of non-dihydrogen producing magnesium bicarbonate with organic acids. Dihydrogen-PQQ resulted in a significant elevation in serum BDNF levels at the six-week follow-up (P = 0.01); conversely, no changes in BDNF levels were observed in the placebo group throughout the study duration (P = 0.27). The authors concluded that despite the limited number of participants included in the study for interpreting clinical parameters, the dihydrogen-PQQ mixture blend shows promise as a potential dietary intervention for enhancing mental orientation and brain metabolism in individuals with age-related mild cognitive decline.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The study used a human clinical study. The hydrogen delivery method was hydrogen-rich water.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.